Management of Spasticity



Fig. 10.1
The majority of descending pathways controlling spinal reflex excitability. (Inhibitory fibres are shown in grey and excitatory fibres are shown in black)



There are two main contributory factors to resistance to movement in the context of post-stroke limb spasticity: a neurogenic component (overactive muscle contraction) and a biomechanical component (stiffening and shortening of the muscle and soft tissues). If left untreated, a vicious cycle occurs in which unopposed contraction due to spasticity of affected muscle groups leads to abnormal limb posture, resulting in soft tissue shortening and further biomechanical changes in the contracted muscles. This, in turn, prevents muscle lengthening and perpetuates further tonicity and formation of contractures [11].


Effect on Lifestyle


People with spasticity often feel embarrassed and frustrated with its limiting effect on daily activities [10, 12]. Severe pain and stiffness, in addition to loss of function, can have a devastating effect on the patient, and problems with sleep due to spasms can lead to fatigue and depression. Spasms in the limbs may also result in problems with positioning and pain that may, in addition, affect sexual relationships. Maintaining hygiene may prove difficult adjacent to areas with increased tone, and patients with spasticity are also at a high risk of developing pressure ulcerations [13]. The patient’s emotional and psychological state can be in constant turmoil, with a strain on their social life, and referral to appropriate specialist agencies may be of benefit [14]. For some patients, spasticity may not only be distressing and painful, but an expensive cause of disability in terms of increased carer burden and reduced rehabilitative progress.

It may be seen, therefore, that secondary complications arising due to spasticity include impaired movement, hygiene, and self-care; poor self esteem, body-image, and sleep patterns; low mood; deformity; weakness; pain; contractures; and pressure ulcers. Patients with spasticity are also more likely to live in institutional care than in their own home, and are significantly more functionally impaired than those without spasticity.


Assessment


Spasticity assessment includes both identifying which muscles or muscle groups are overactive, and also determining the effect of spasticity on all aspects of patient function, including mobility, employment, and activities of daily living. Furthermore, factors such as cognition and deficits of sensation, attention, and vision (that may exacerbate spasticity) need to be evaluated. A systematic approach to assessment is required by a multidisciplinary team involving medical specialists (often from rehabilitation medicine or neurology disciplines), nurses, and allied healthcare professionals including physiotherapists, occupational therapists, orthotists, and rehabilitation engineers.

Formal assessment of tone may be measured using clinical scales such as the modified Ashworth and Tardieu scales (Table 10.1), or using techniques such as electrogoniometry to measure range of movement across a joint or quantitative neurophysiology [15, 16]. Whilst the latter two techniques are not widely available or practical in routine clinical practice, the clinical scales require no instrumentation, are quick to carry out, and have good inter- and intra-observer reliability [1719]. The modified Ashworth scale is most widely used but its validity, reliability, and sensitivity are acknowledged to have limitations [20]. A number of scales also exist to assess patients’ self-reported health status including pain, comfort, mobility, continence, and fatigue [21, 22]. Since pain and stiffness are important and troublesome symptoms in relation to spasticity, visual analogue, and verbal rating scales are often usefully employed to record objective change following treatment. In those who have communication deficits or who lack numerical skills, pictoral rating scales may be used. In people with severe cognitive deficits and problems with communication, tools such as the AbilityQ may be used to test an individual’s ability to use different types of scales and thus help present questions in an appropriate format [23].


Table 10.1
Modified Ashworth and Tardieu scales











































Modified Ashworth scale

0

No increase in muscle tone

1

Slight increase in muscle tone, manifested by a catch and release, or by minimal resistance at the end of the range of motion when the affected part(s) is moved in flexion or extension

1+

Slight increase in muscle tone, manifested by a catch, followed by minimal resistance throughout the remainder of the range of movement

2

More marked increase in muscle tone through most of the range of movement, but affected parts easily moved

3

Considerable increase in muscle tone, passive movement difficult

4

Affected parts rigid in flexion or extension

Modified Tardieu scale

0

No resistance throughout the course of the passive movement

1

Slight resistance throughout the course of the passive movement, with no clear catch at precise angle

2

Clear catch at precise angle, interrupting the passive movement, followed by release

3

Fatiguable clonus (<10 s when maintaining pressure) occurring at precise angle

4

Infatiguable clonus (>10 s when maintaining pressure) occurring at precise angle

In patients with selective, underlying, voluntary movement in limbs with increased tone limiting “active” function, functional assessments are helpful tools to guide rehabilitative progress. Examples include the Action Research Arm, Frenchay, and nine-hole peg tests for the upper limbs; the Functional Ambulation Category, 10-m walking time, and 6-min walking distance tests for lower limbs [11]. Passive function can also be assessed using verbal or visual analogue ratings of “ease of care”, timed-care tasks (for example, the time taken for washing and dressing), or formal scales that measure dependency or carer burden (such as the Barthel’s index of activities of daily living).

First introduced in the 1960s, goal setting and its attainment has developed into a crucial element of spasticity assessment [24]. The attainment of goals following interventions varies amongst patients, and a single outcome measure is not always able to capture all domains. The Goal Attainment Scale (that involves simple recording of treatment goals achieved) has proved useful in terms of being suitable for patients with health problems, who need a multidimensional but individualised approach to treatment planning and outcome [25].


Purpose of Treatment


The management of muscle tone is an integral part of therapy for patients suffering from spasticity. Muscle tone is a dynamic, complex process that is part of an overall pattern of posture and movement. Appropriate management of tone is one of the fundamental principles of the Bobath method of facilitative physiotherapy, which gives priority to normalisation of tone and improving symmetry even at the cost of postponing standing or walking. However, this pre-occupation with normalisation of tone is not supported by evidence, and there are several other approaches which combine early mobilisation with active muscle tone management during rehabilitation [26].

The management of abnormal tone and spasticity is difficult, as it depends on achieving the right balance between hypo- and hypertonia between different muscle groups. The problem is compounded by the fact that spasticity varies between different groups of muscles and times of the day, and is affected by the emotional state of the patient, activity being undertaken, limb posture, and the timing of medication. Inappropriate exercise can result in inappropriate tone patterns, to the ultimate detriment of the patient. If not managed correctly, spasticity leads to poor gait patterns, contractures, and loss of function.

Spasticity should be considered in relation to other impairments, and in the context of therapy goals, because interventions directed solely at reduction of spasticity are unlikely to result in significant functional gains. The therapeutic management of spasticity is closely related to the aims of rehabilitation; these include avoidance of complications, restoration of movement, re-education of movement and gait, development of self-dependency, and social integration, improving self-esteem and overall body image, as well as promoting new neurophysiological dynamics and neural plasticity. A further aim of treating spasticity is to relieve pain and other distressing symptoms that have a detrimental effect on quality of life.

There should be a multidisciplinary team approach to spasticity management, through which realistic goals and expectations of the patients, families, and caregivers can be established. It is important that treatment be tailored to the individual patient, and factors that may aggravate spasticity, including inter-current medical illness, medications that increase muscle tone, and emotional stressors, should be managed in the first instance [27, 28]. It should also be borne in mind that some patients may be able to use their increased tone to aid with function and maintaining postural control and ambulation, and so global reduction of tone may be destabilising. Appreciation of the differing treatment options for focal versus global spasticity is important, as is the awareness that treatment of spasticity may ameliorate weakness in affected limbs.


Non-pharmacological Approaches



Prevention of Aggravating Factors


In addition to causing pain and discomfort, pain and discomfort themselves and other nociceptive stimuli aggravate the symptoms from spasticity. As such, a multidisciplinary approach to identifying any aggravating factors and treating them is crucial to management of spasticity. Besides pain and discomfort, the other common aggravating factors are constipation, infection, tight clothing, and poor postural management.


Education and Psychological Support


All members of the multidisciplinary team should provide education to patients and carers about the causes and nature of spasticity and, if needed, strategies should be employed to reduce emotional stress. Patients and carers should be provided with verbal and written information, including information leaflets, to help them understand how spasticity affects day-to-day function and how to avoid any triggers. Patients need to be made aware of how visceral and cutaneous stimuli may affect their spasticity.


Involvement of Physiotherapy/Occupational Therapy


Treatment of abnormal tone is initiated by physiotherapists, who can offer a range of interventions including physical therapy, attention to posture and seating, and orthotic devices [2931]. Correct positioning is a critical aspect of management in order that the patient is in a balanced and stable posture that is comfortable and maximises function. Optimal seating is planned and implemented by occupational therapists and physiotherapists, and this may involve the use of a variety of seating adjustments such as foot straps; knee blocks; and head, neck, and trunk supports [32]. Occupational therapists and physiotherapists also are responsible for application of casts and splints to minimise spasticity and prevent contractures [33]. Implementation of planned seating and positioning strategies by nurses and carers throughout the day and night is crucial to management of spasticity and prevention of its complications.

Physiotherapists and occupational therapists should complete their assessments over a period of time and in conjunction with other members of the patient’s multidisciplinary team, including the patient’s carers and nurses, in order to optimise management strategies. It is essential that such strategies attain the correct balance between movement and positioning and continuity of care, particularly across the interfaces of primary and secondary care, involving community rehabilitation teams and care agencies, facilitates the appropriate choice and timing of any management intervention [21].


Pharmacological Treatments


Drug therapy is generally initiated at low dosages and then gradually increased in an attempt to avoid adverse effects [21, 28]. Optimal therapy is the lowest effective dosage. Drug treatments should be contemplated early in severe cases of spasticity, where secondary problems often develop and combination therapy using oral medications and focal injections of botulinum toxin or other chemodenervating agents may allow for the best control of spasticity with the least side effects [34].


Oral Medication for Treatment of Global Spasticity


Baclofen, tizanidine, diazepam (that act centrally) and dantrolene (that acts peripherally on skeletal muscle) are the most widely used drugs in patients with global spasticity. Other agents such as gabapentin, clonazepam, clonidine, and cyproheptadine have also been used for the management of spasticity, but in fewer patients.


Baclofen

This is the most widely used anti-spastic drug whose clinical benefits mainly relate to reducing muscle spasms and hyper-reflexia [35]. Baclofen is structurally similar to the inhibitory neurotransmitter GABA (gamma-aminobutyric acid) and increases inhibition both pre-synaptically and post-synaptically by selectively binding to GABA-B receptors [36]. The common starting dose is 5 mg three times daily that then may be titrated up to a maximum daily dose of 60–100 mg in divided doses. Side effects are predominantly from central depressant properties including sedation, ataxia, weakness, and fatigue [35]. Tolerance to the medication may develop, and baclofen must be slowly weaned to prevent withdrawal effects such as seizures, hallucinations, and increased spasticity. Limitations of baclofen use include its lowering of seizure threshold and patients’ intolerance of side effects at higher doses.


Tizanidine

This is an imidazoline central alpha-adrenoceptor agonist that has been confirmed to be a useful anti-spastic agent. It is a short-acting drug with dose-dependent linear pharmacokinetics and larger inter-patient variability compared with other anti-spastic agents [37]. Patients report less muscle weakness from tizanidine than baclofen or diazepam, but side effects include drowsiness, fatiguability, dizziness, dry mouth, and gastrointestinal disturbance [3739]. There is a small incidence of abnormal liver function tests and these should be monitored at intervals during therapy [40]. Tizanidine may be combined with baclofen, presenting the opportunity to reduce the dosage of both drugs, but additive adverse effects, including sedation, may occur.


Diazepam

This was one of the first anti-spastic agents, but in view of its potential to cause significant fatigue and drowsiness, is only recommended for relieving painful nocturnal spasms [35, 41]. Midazolam, another benzodiazepine, is sometimes useful to help distinguish between patients with active spasticity and contractures.


Dantrolene

This is a useful anti-spastic agent that has a similar range of side effects to baclofen, but is less likely than the other agents to cause drowsiness, confusion, and other central effects because of its mechanism of action. Dantrolene has been shown to decrease muscle tone, clonus, and muscle spasm, but since its action is not selective for spastic muscles, it may cause generalised weakness, including weakness of the respiratory muscles [36]. It can also cause hepatitis, and so periodic monitoring of liver function tests is advised [42, 43].


Gabapentin

Gabapentin interacts with voltage-sensitive calcium channels in cortical neurons and increases the synaptic concentration of GABA, enhances GABA responses at non-synaptic sites in neuronal tissues, and reduces the release of mono-amine neurotransmitters. It is generally used as an anticonvulsant and analgesic for neuropathic pain. The most common side effects include dizziness, fatigue, drowsiness, weight gain, and peripheral oedema. In a randomised, double-blind, placebo-controlled study involving 30 patients with upper motor neurone spasticity secondary to a pyramidal tract lesion, Formica et al. showed Gabapentin in doses of 2,700–3,600 mg/day to provide significant improvement in Ashworth scores but no change in spasm frequency [44].

Only gold members can continue reading. Log In or Register to continue

Stay updated, free articles. Join our Telegram channel

Jun 27, 2017 | Posted by in NEUROLOGY | Comments Off on Management of Spasticity

Full access? Get Clinical Tree

Get Clinical Tree app for offline access